Xeltis, a Netherlands-based developer of living cardiovascular implants, has received €12.5 million in additional funding from the European Innovation Council (EIC) Fund. This financial boost, combined with the Series D2 financing round announced in February 2023, brings the company's total funding to €44.5 million.
The funding will support the clinical development of Xeltis’ implants, notably the first-in-human (FIH) trial of its aXess vascular graft designed for patients with chronic kidney disease requiring hemodialysis. It will also support an ongoing pivotal trial for aXess, enrolling patients across Europe, and advance Xeltis’ coronary artery bypass graft program.
Endogenous Tissue Restoration
Xeltis' technology centers around its endogenous tissue restoration platform. This approach utilizes a polymer implant that facilitates the regeneration of the patient's own tissue. Over time, the polymer is absorbed, leaving behind a new, living, and durable vessel. The aXess implantable blood vessel, intended for hemodialysis vascular access, represents the company's most advanced product currently in clinical development.
Clinical Data
Earlier in the year, Xeltis presented 6-month data from the aXess-FIH study. Professor Matteo Tozzi, MD, presented the data at the 13th Congress of the Vascular Access Society in Porto, Portugal. These results underscore the potential of the aXess vascular graft in improving outcomes for patients requiring hemodialysis.
